Highlights Newsletter 1
This newsletter presents you the following key sessions:
3. Neoadjuvant nivolumab plus ipilimumab as a novel standard of care in resectable stage III melanoma
This newsletter presents you the following key sessions:
3. Neoadjuvant nivolumab plus ipilimumab as a novel standard of care in resectable stage III melanoma
Medical writer